Colony Group’s United Therapeutics UTHR Stock Holding History

Colony Group’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,511	Closed	-$200K	–	768
2019 Q3	$200K	Sell	2,511 -1,489	-37%	-$120K	0.01%	676
2019 Q2	$312K	Sell	4,000 -804	-17%	-$75.2K	0.01%	593
2019 Q1	$564K	Hold	4,804	–	–	0.02%	374
2018 Q4	$523K	Hold	4,804	–	–	0.03%	333
2018 Q3	$614K	Hold	4,804	–	–	0.03%	313
2018 Q2	$544K	Sell	4,804 -40,822	-89%	-$4.49M	0.03%	329
2018 Q1	$5.13M	Buy	+45,626	New	+$5.8M	0.28%	90

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Colony Group's UTHR Position: Q4 2019 in Review

Colony Group sold out of United Therapeutics (UTHR) in Q4 2019, closing a stake of 2,511 shares — an estimated $200K sold.

Colony Group first reported a position in UTHR in Q1 2018 and held it in 7 quarters. The position peaked at $5.13M in Q1 2018. 320 funds tracked by Wall St. Rank hold UTHR as of Q4 2019.

Colony Group reported no remaining United Therapeutics position as of Q4 2019 after selling out during the quarter.
Colony Group sold 2,511 United Therapeutics shares in Q4 2019, an estimated $200K.
Colony Group first reported a position in United Therapeutics in Q1 2018 and held it in 7 quarters.
Colony Group's United Therapeutics position peaked at $5.13M in Q1 2018.
320 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2019.

Based on Colony Group's 13F filing for Q4 2019, filed 18 Feb 2020.